Whanin Pharm Co Ltd

Whanin Pharm Co Ltd maintains a strong liquidity position with a current ratio of 4.04, indicating the company can easily cover its short-term liabilities with its current assets. The company's cash and equivalents amount to 63,580,166,010 KRW, which is a significant portion of its total assets. The absence of long-term debt and a debt-to-equity ratio of 0.0 further reinforce the company's robust capital structure.

The company's profitability metrics show a return on equity (ROE) of 3.23% and a return on assets (ROA) of 2.84%. These figures are below the typical thresholds for high-performing pharmaceutical firms, suggesting that the company may not be generating returns as efficiently as its peers. The net income of 13,595,213,600 KRW and operating income of 13,018,531,800 KRW indicate a profitable operation, but the gross profit margin of 34.13% (calculated from the given figures) suggests there is room for improvement in cost management.

Whanin Pharm Co Ltd's revenue is concentrated in a single business segment, as no segmental breakdown is provided in the available data. The company's geographic exposure is primarily domestic, with no significant international operations disclosed. This concentration may pose a risk if the domestic market experiences economic downturns or regulatory changes.

The company's growth trajectory is not explicitly detailed in the available data, but the free cash flow of 12,209,932,950 KRW and operating cash flow of 9,043,600,260 KRW suggest a stable cash-generating business. The capital expenditure of -6,182,489,650 KRW indicates that the company is not heavily investing in new projects, which may limit its future growth potential.

The risk assessment for Whanin Pharm Co Ltd indicates low liquidity and dilution risks. The company has no immediate filing-based liquidity or dilution flags, and the absence of long-term debt and the presence of substantial cash reserves further support this assessment. The dilution potential is also low, with no signs of recent or planned equity issuances that could dilute existing shareholders.

Recent events and filings for Whanin Pharm Co Ltd do not show any significant developments that would impact the company's financial position or strategic direction. The company's analyst estimates are relatively neutral, with a mean recommendation of 2.00 and a mean price target of 17,000.00 KRW. The lack of strong buy or hold recommendations suggests that analysts are not particularly bullish on the company's prospects.

Analysts project 71.7% upside to a consensus target price of 17,000 KRW, signaling strong market confidence.

Free cash flow surged 569.8% year-over-year to 12.2 billion KRW, demonstrating significant improvement in cash generation.

The company maintains a zero debt-to-equity ratio, ranking above the 75th percentile within the pharmaceutical cohort.

Net margin of 5.33% outperforms the cohort median of 3.9%, reflecting better profitability relative to peers.

Net income CAGR of -15.5% over four years indicates a persistent long-term decline in profitability.

Cash conversion ratio of 0.67 falls below the pharmaceutical cohort median of 0.95, suggesting weaker cash efficiency.

Revenue KRW 65.14B, −1,7% YoY; Operating income +62,4% YoY.

• ▍Revenue KRW 65.14B, −1,7% YoY
• ▍Operating income +62,4% YoY
• ▍Net income −43,9% YoY
• ▍Free cash flow +29,6% YoY
• ▍Net margin 3.1%

Revenue KRW 65.74B, −3,5% YoY; Operating income −32,8% YoY.

• ▍Revenue KRW 65.74B, −3,5% YoY
• ▍Operating income −32,8% YoY
• ▍Net income −27,5% YoY
• ▍Free cash flow +40,9% YoY
• ▍Net margin 5.0%

Revenue KRW 64.14B, +0,8% YoY; Operating income −56,1% YoY.

• ▍Revenue KRW 64.14B, +0,8% YoY
• ▍Operating income −56,1% YoY
• ▍Net income −48,7% YoY
• ▍Free cash flow +71,9% YoY
• ▍Net margin 5.0%

Revenue KRW 60.20B, −2,3% YoY; Operating income −36,5% YoY.

• ▍Revenue KRW 60.20B, −2,3% YoY
• ▍Operating income −36,5% YoY
• ▍Net income −43,6% YoY
• ▍Free cash flow +4 247,1% YoY
• ▍Net margin 8.5%

Revenue KRW 66.25B; Operating income KRW 913.1M.

• ▍Revenue KRW 66.25B
• ▍Operating income KRW 913.1M
• ▍Net margin 5.4%

Revenue KRW 68.11B; Operating income KRW 5.29B.

• ▍Revenue KRW 68.11B
• ▍Operating income KRW 5.29B
• ▍Net margin 6.6%

Revenue KRW 63.62B; Operating income KRW 6.98B.

• ▍Revenue KRW 63.62B
• ▍Operating income KRW 6.98B
• ▍Net margin 9.8%

Revenue KRW 61.61B; Operating income KRW 8.32B.

• ▍Revenue KRW 61.61B
• ▍Operating income KRW 8.32B
• ▍Net margin 14.7%

Revenue KRW 255.21B, −1,7% YoY; Operating income −39,4% YoY.

• ▍Revenue KRW 255.21B, −1,7% YoY
• ▍Operating income −39,4% YoY
• ▍Net income −41,9% YoY
• ▍Free cash flow +569,8% YoY
• ▍Net margin 5.3%

Revenue KRW 259.60B, +12,7% YoY; Operating income −28,8% YoY.

• ▍Revenue KRW 259.60B, +12,7% YoY
• ▍Operating income −28,8% YoY
• ▍Net income −21,5% YoY
• ▍Free cash flow −2 317,0% YoY
• ▍Net margin 9.0%

Revenue KRW 230.39B, +15,8% YoY; Operating income +1,2% YoY.

• ▍Revenue KRW 230.39B, +15,8% YoY
• ▍Operating income +1,2% YoY
• ▍Net income +24,5% YoY
• ▍Free cash flow +99,8% YoY
• ▍Net margin 12.9%

Revenue KRW 198.93B, +11,9% YoY; Operating income −4,7% YoY.

• ▍Revenue KRW 198.93B, +11,9% YoY
• ▍Operating income −4,7% YoY
• ▍Net income −10,3% YoY
• ▍Free cash flow −312,2% YoY
• ▍Net margin 12.0%